LONDON, Sept 20 (Reuters) - An experimental drug forDuchenne muscular dystrophy from GlaxoSmithKline andProsensa failed to meet its goal in a late-stageclinical trial, the companies said on Friday.
The drug, drisapersen, did not show a statisticallysignificant improvement in the distance that patients could walkin six minutes compared to placebo in the Phase III test.